Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes

Thrombosis Journal

Volumn 8, Issue , 2010, Pages

  Opstad, Trine B ^a   Pettersen, Alf T ^a   Weiss, Thomas ^a   Arnesen, Harald ^a,b   Seljeflot, Ingebjørg ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; CLOPIDOGREL; CYTOSINE; GUANOSINE; THROMBOPLASTIN; THYMIDINE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HETEROZYGOSITY; HUMAN; INTRON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77951875025     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-8-7     Document Type: Article

References (30)

1. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999, 96:2311-2315. 10.1073/pnas.96.5.2311, 26780, 10051638.
2. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989, 338:518-520. 10.1038/338518a0, 2927510.
3. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001, 86:959-972.
4. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990, 87:8869-8873. 10.1073/pnas.87.22.8869, 55061, 2247459.
5. Broze GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995, 74:90-93.
6. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992, 3:439-449.
7. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989, 86:2839-2843. 10.1073/pnas.86.8.2839, 287014, 2704749.
8. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999, 188:180-188. 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO;2-Q, 10398162.
9. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998, 79:495-499.
10. Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 1998, 102:605-608. 10.1046/j.1365-2141.1998.00804.x, 9695980.
11. Ott I. Tissue factor in acute coronary syndromes. Semin Vasc Med 2003, 3:185-192. 10.1055/s-2003-40676, 15199481.
12. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Munzel T, Peetz D, Nicaud V, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007, 5:475-482. 10.1111/j.1538-7836.2007.02372.x, 17204132.
13. Seljeflot I, Hurlen M, Hole T, Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res 2003, 111:369-372. 10.1016/j.thromres.2003.09.019, 14698655.
14. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004, 27:2898-2904. 10.2337/diacare.27.12.2898, 15562204.
15. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997, 241:485-492.
16. Calles-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999, 10:23-30. 10.1097/00019501-199901000-00004, 10196684.
17. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001, 15:44-54. 10.1016/S1056-8727(00)00132-X, 11259926.
18. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007, 92:4352-4358. 10.1210/jc.2007-0933, 17785358.
19. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M, Juhan-Vague I. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001, 85:999-1003.
20. Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G, Ruidavets JB, Emmerich J, et al. Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol 2000, 20:892-898.
21. Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 2006, 26:2800-2806. 10.1161/01.ATV.0000247249.82030.94, 17008590.
22. Malarstig A, Tenno T, Johnston N, Lagerqvist B, Axelsson T, Syvanen AC, Wallentin L, Siegbahn A. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol 2005, 25:2667-2672. 10.1161/01.ATV.0000191637.48129.9b, 16239598.
23. Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schomig A, Kastrati A. Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis 2004, 177:189-191. 10.1016/j.atherosclerosis.2004.07.006, 15488883.
24. Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, Garbarz M, Dhermy D, Arveiler D, Evans A, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264 M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999, 19:862-869.
25. Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, Olliver V, Aumont MC, de Prost D. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000, 84:244-249.
26. Moatti D, Meirhaeghe A, Ollivier V, Bauters C, Amouyel P, de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis 2001, 12:317-323. 10.1097/00001721-200106000-00013, 11460016.
27. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38:353-356. 10.1080/14017430410024324, 15804802.
28. Sambola A, Fuster V, Badimon JJ. [Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes]. Rev Esp Cardiol 2003, 56:1001-1009. 10.1157/13052389, 14563295.
29. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996, 16:802-808.
30. Dahm AE, Andersen TO, Rosendaal F, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005, 3:651-658. 10.1111/j.1538-7836.2005.01237.x, 15842349.